These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


950 related items for PubMed ID: 18835761

  • 1. Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model.
    Song JY, Cheong HJ, Lee J, Sung AK, Kim WJ.
    Int J Antimicrob Agents; 2009 Jan; 33(1):33-9. PubMed ID: 18835761
    [Abstract] [Full Text] [Related]

  • 2. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model.
    Montero A, Ariza J, Corbella X, Doménech A, Cabellos C, Ayats J, Tubau F, Borraz C, Gudiol F.
    J Antimicrob Chemother; 2004 Dec; 54(6):1085-91. PubMed ID: 15546972
    [Abstract] [Full Text] [Related]

  • 3. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections.
    Saballs M, Pujol M, Tubau F, Peña C, Montero A, Domínguez MA, Gudiol F, Ariza J.
    J Antimicrob Chemother; 2006 Sep; 58(3):697-700. PubMed ID: 16895941
    [Abstract] [Full Text] [Related]

  • 4. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.
    Song JY, Kee SY, Hwang IS, Seo YB, Jeong HW, Kim WJ, Cheong HJ.
    J Antimicrob Chemother; 2007 Aug; 60(2):317-22. PubMed ID: 17540672
    [Abstract] [Full Text] [Related]

  • 5. Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam.
    Pachón-Ibáñez ME, Fernández-Cuenca F, Docobo-Pérez F, Pachón J, Pascual A.
    J Antimicrob Chemother; 2006 Sep; 58(3):689-92. PubMed ID: 16870647
    [Abstract] [Full Text] [Related]

  • 6. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases.
    Tripodi MF, Durante-Mangoni E, Fortunato R, Utili R, Zarrilli R.
    Int J Antimicrob Agents; 2007 Dec; 30(6):537-40. PubMed ID: 17851050
    [Abstract] [Full Text] [Related]

  • 7. Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Song JY, Lee J, Heo JY, Noh JY, Kim WJ, Cheong HJ, Hwang IS.
    Int J Antimicrob Agents; 2008 Sep; 32(3):281-4. PubMed ID: 18650070
    [No Abstract] [Full Text] [Related]

  • 8. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii.
    Motaouakkil S, Charra B, Hachimi A, Nejmi H, Benslama A, Elmdaghri N, Belabbes H, Benbachir M.
    J Infect; 2006 Oct; 53(4):274-8. PubMed ID: 16442632
    [Abstract] [Full Text] [Related]

  • 9. Intratracheal colistin sulfate for BALB/c mice with early pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Chiang SR, Chuang YC, Tang HJ, Chen CC, Chen CH, Lee NY, Chou CH, Ko WC.
    Crit Care Med; 2009 Sep; 37(9):2590-5. PubMed ID: 19623044
    [Abstract] [Full Text] [Related]

  • 10. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO.
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia.
    Bernabeu-Wittel M, Pichardo C, García-Curiel A, Pachón-Ibáñez ME, Ibáñez-Martínez J, Jiménez-Mejías ME, Pachón J.
    Clin Microbiol Infect; 2005 Apr; 11(4):319-25. PubMed ID: 15760430
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of sulbactam and its combination with imipenem, colistin and tigecycline in an experimental model of carbapenem-resistant Acinetobacter baumannii sepsis.
    Dinc G, Demiraslan H, Elmali F, Ahmed SS, Metan G, Alp E, Doganay M.
    Chemotherapy; 2013 Apr; 59(5):325-9. PubMed ID: 24525528
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of various combinations of antimicrobials against carbapenem-resistant Acinetobacter species in Singapore.
    Lim TP, Tan TY, Lee W, Sasikala S, Tan TT, Hsu LY, Kwa AL.
    J Antibiot (Tokyo); 2009 Dec; 62(12):675-9. PubMed ID: 19876075
    [Abstract] [Full Text] [Related]

  • 14. Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events.
    Petrosillo N, Chinello P, Proietti MF, Cecchini L, Masala M, Franchi C, Venditti M, Esposito S, Nicastri E.
    Clin Microbiol Infect; 2005 Aug; 11(8):682-3. PubMed ID: 16008625
    [No Abstract] [Full Text] [Related]

  • 15. Comparative evaluation of intratracheal colistimethate sodium, imipenem, and meropenem in BALB/c mice with carbapenem-resistant Acinetobacter baumannii pneumonia.
    Tang HJ, Chuang YC, Ko WC, Chen CC, Shieh JM, Chen CH, Lee NY, Chiang SR.
    Int J Infect Dis; 2012 Jan; 16(1):e34-40. PubMed ID: 22088863
    [Abstract] [Full Text] [Related]

  • 16. Antibacterial activity of carbapenem-based combinations againts multidrug-resistant Acinetobacter baumannii.
    Pongpech P, Amornnopparattanakul S, Panapakdee S, Fungwithaya S, Nannha P, Dhiraputra C, Leelarasamee A.
    J Med Assoc Thai; 2010 Feb; 93(2):161-71. PubMed ID: 20301995
    [Abstract] [Full Text] [Related]

  • 17. [Nosocomial pneumonia caused by multiresistant Acinetobacter baumanii treated by colistin and rifampicin].
    Motaouakkil S, Charra B, Hachimi A, Benslama A.
    Ann Fr Anesth Reanim; 2006 May; 25(5):543-4. PubMed ID: 16488103
    [No Abstract] [Full Text] [Related]

  • 18. Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin.
    Pantopoulou A, Giamarellos-Bourboulis EJ, Raftogannis M, Tsaganos T, Dontas I, Koutoukas P, Baziaka F, Giamarellou H, Perrea D.
    Int J Antimicrob Agents; 2007 Jan; 29(1):51-5. PubMed ID: 17189095
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
    Pachón-Ibáñez ME, Docobo-Pérez F, López-Rojas R, Domínguez-Herrera J, Jiménez-Mejias ME, García-Curiel A, Pichardo C, Jiménez L, Pachón J.
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1165-72. PubMed ID: 20047914
    [Abstract] [Full Text] [Related]

  • 20. In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates.
    Tan TY, Ng LS, Tan E, Huang G.
    J Antimicrob Chemother; 2007 Aug; 60(2):421-3. PubMed ID: 17540671
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 48.